Medical Properties Trust stock falls after Idaho hospital sale and debt concerns

Medical Properties Trust stock (ISIN US58463J3041) ended the last completed trading day at USD 3.39 on the New York Stock Exchange on September 18, 2026, down 5.8 percent from the prior close and around 29.4 percent lower than its level in March 2026, underscoring how restructuring moves and debt worries continue to shape the share price for real estate investment trust investors.

Hospital sale brings in USD 371 million cash

The most immediate catalyst for Medical Properties Trust stock is the completion of a major asset sale in Idaho that strengthens the company’s liquidity but leaves questions about long-term earnings power. According to Businesswire on September 16, 2026, Medical Properties Trust completed the sale of two Idaho hospitals for USD 371 million in cash to a third-party buyer, with the proceeds earmarked primarily for debt reduction and general corporate purposes.

As MarketScreener reported on September 16, 2026, the transaction price of USD 371 million compares with a book value for the properties that suggests Medical Properties Trust crystallized modest gains, and management highlighted that the sale would reduce net debt and improve the company’s leverage profile without materially affecting current funds from operations.

Stock reaction and year-to-date performance

The market’s reaction to the Idaho deal has been mixed, with short-term volatility but no immediate trend reversal for Medical Properties Trust stock. Per price data summarized by MarketBeat as of September 18, 2026, the shares closed at USD 3.39 on the NYSE, down USD 0.21 or 5.83 percent on the day, after trading near USD 3.60 earlier in the week in the run-up to the announcement that the Idaho sale had closed.

According to MarketBeat on September 19, 2026, Medical Properties Trust stock was around USD 4.80 on March 13, 2026 and has since fallen by about 29.4 percent to USD 3.39, illustrating that despite asset sales and debt management efforts, equity investors continue to discount the REIT’s tenant exposure and leverage compared with earlier in the year.

Recent debt exchange and ongoing balance sheet risks

Beyond the Idaho transaction, debt structure and tenant concentration remain central to the investment case for Medical Properties Trust stock. As Seeking Alpha argued in an analysis dated September 15, 2026, a recent debt exchange by Medical Properties Trust, in which the company refinanced portions of its maturities, helped to relieve near-term refinancing pressure but did not fully resolve fundamental issues related to leverage, asset quality and exposure to financially weaker hospital operators.

The same analysis by Seeking Alpha on September 15, 2026 highlighted that Medical Properties Trust continues to carry a high debt load relative to its equity market value and that a significant share of its rental income is tied to tenants that have faced operating challenges, reinforcing why even positive steps like the USD 371 million Idaho sale have not yet resulted in a sustained rerating of the shares.

Most recent fundamental figures and guidance

For a longer-term perspective, investors in Medical Properties Trust stock are watching how asset sales and debt adjustments filter through to operating performance and guidance. According to MarketScreener summarizing the company’s latest interim results for the quarter ended June 30, 2026, Medical Properties Trust generated revenue of roughly USD 250 million in Q2 2026, which represented a mid-single-digit percent decline compared with the same quarter a year earlier as disposals and tenant restructuring weighed on rental streams.

In the same Q2 2026 reporting cycle, Medical Properties Trust’s funds from operations per share stood near USD 0.25, down from approximately USD 0.28 in Q2 2025, according to figures compiled by MarketScreener, reflecting both asset sales and pressure on certain tenants but still covering the current dividend payout.

Medical Properties Trust also maintained full-year 2026 guidance for funds from operations in a range consistent with prior indications, albeit at the lower end of earlier expectations, as of its Q2 2026 disclosure, according to guidance commentary cited by MarketScreener, signaling that management sees the combination of asset sales and operational adjustments as sufficient to keep underlying earnings broadly stable in the near term.

Analyst sentiment and valuation backdrop

Analyst views on Medical Properties Trust stock remain divided between those who focus on high yield and discounted valuation and those who emphasize tenant and balance sheet risks. As MarketBeat compiled on September 19, 2026, Medical Properties Trust carries a mix of buy, hold and sell ratings, with the average twelve-month price target standing meaningfully above the current USD 3.39 share price, suggesting that if management can continue to execute asset sales and de-leveraging without major tenant failures, some analysts see potential for upside from today’s depressed level.

At the same time, the September 15, 2026 commentary from Seeking Alpha emphasized that even after recent debt exchanges and the Idaho sale, Medical Properties Trust’s valuation should be considered in light of unresolved structural issues, meaning the discount to book value and to historical price levels may persist until the market gains greater confidence in tenant health and the durability of cash flows.

Stock level and market metrics

From a trading perspective, Medical Properties Trust stock is currently priced well below typical historical ranges for the REIT, and that gap is visible in common valuation metrics. Per the same price overview from MarketBeat on September 18, 2026, the shares at USD 3.39 sit far under their 52-week high, with the 52-week low close to the current price level, and Medical Properties Trust’s market capitalization now measures in the low single-digit billions of dollars, a fraction of where it stood before tenant problems and debt concerns intensified in recent years.

For investors, the key question is whether transactions such as the USD 371 million Idaho hospital sale and the recent debt exchange mark the start of a sustainable repair of the balance sheet or simply buy time; until upcoming quarters confirm that funds from operations and occupancy are stabilizing, Medical Properties Trust stock is likely to remain sensitive to every new data point on tenant performance and asset sales.

More news and analyses on Medical Properties Trust stock